I

Inspira Mental Health Management | Inspira Clinical Research

Research site

(Unclaimed)

Location

405 Hostos Avenuve, San Juan, Puerto Rico, United States of America

Site insights

Top conditions

Top treatments

Cariprazine

SPD489

Lurasidone

Agomelatine

Donanemab

KarXT

LY3002813

Rivastigmine

Simufilam

Levomilnacipran

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 16 total trials

A Donanemab (LY3002813) Prevention Study in Participants With Alzheimer's Disease (TRAILBLAZER-ALZ 3)

The main purpose of this study is to evaluate the safety and efficacy of donanemab in participants with preclinical Alzheimer's Disease (AD).

Enrolling

Alzheimer Disease

Drug: Donanemab

Drug: Placebo

A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

The reason for this study is to see how safe and effective the study drug donanemab is in participants with early Alzheimer's disease.Additional part...

Active, not recruiting

Alzheimer Disease

Drug: Donanemab

Drug: Placebo

An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)

This is a Phase 3, multicenter, 56-week, outpatient, open-label (OL) study to evaluate the long-term safety, tolerability, and efficacy of KarXT in d...

Active, not recruiting

Schizophrenia

Drug: Xanomeline and Trospium Chloride Capsules

Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease (REFOCUS-ALZ)

A 76-week safety and efficacy study of simufilam (PTI-125) given twice daily to participants with mild-to-moderate Alzheimer's disease (AD) for 76 we...

Active, not recruiting

Alzheimer Disease

Drug: Placebo

Drug: Simufilam